Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals

Summary

This study aims to screen and validate multi-scale bio-markers for early diagnosis and medication monitoring for early schizophrenia, including the genetic, neurobiochemistry, neuroimaging and eletrophysiological measures. Based on the validated bio-markers, the present study further tries to build several prediction models for early differential diagnosis of schizophrenia from healthy controls and other mental diseases (such as the major depression and anxiety disorders), biological sub-typing and diagnosis of the schizophrenia sub-types, and early prediction of the medication effects.

Conditions

• Schizophrenia
• Major Depressive Disorder
• Anxiety Disorders

Interventions

DRUG

Risperidone

Risperidone tablet

DRUG

Olanzapine

Olanzapine tablet

DRUG

Aripiprazole

Aripiprazole tablet

Sponsors & Collaborators

• Shanghai Mental Health Center

  collaborator OTHER

• Nanjing Medical University

  collaborator OTHER

• Tianjin Anding Hospital

  collaborator OTHER

• Harbin First Specialist Hospital

  collaborator UNKNOWN

• First Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Anhui Mental Health Center

  collaborator UNKNOWN

• Wuhan Psychiatric Hospital

  collaborator UNKNOWN

• Wenzhou Seventh People's Hospital

  collaborator OTHER_GOV

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Tianjin Medical University General Hospital

  lead OTHER

Principal Investigators

• Chunshui Yu, MD · Tianjin Medical University General Hospital

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

45 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2018-09-01

Primary Completion

2020-06-30

Completion

2020-12-31

Countries

• China

Study Locations